Development of generic low molecular weight heparins: A perspective

Hematology/Oncology Clinics of North America

Volumn 19, Issue 1, 2005, Pages 53-68

  Fareed, Jawed ^a   Leong, Wendy ^b   Hoppensteadt, Debra A ^a   Jeske, Walter P ^a   Walenga, Jeanine ^a   Bick, Rodger L ^c  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ARDEPARIN; CERTOPARIN; CLOPIDOGREL; CUTENOX; DALTEPARIN; ENOXAPARIN; GENERIC DRUG; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; REVIPARIN; TINZAPARIN; WARFARIN;

ANTICOAGULATION; CLINICAL TRIAL; CORONARY ARTERY DISEASE; COST BENEFIT ANALYSIS; DEEP VEIN THROMBOSIS; DISEASE SEVERITY; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ELIMINATION; DRUG INDUSTRY; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; MOLECULAR WEIGHT; PATENT; PATIENT CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; DRUG APPROVAL; PHARMACOKINETICS;

DRUG APPROVAL; DRUGS, GENERIC; HEPARIN, LOW-MOLECULAR-WEIGHT; THERAPEUTIC EQUIVALENCY;

EID: 15544380028     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2004.09.005     Document Type: Review

References (29)

1. G. Merli, G. Vanscoy, and T.L. Rihn Applying scientific criteria to therapeutic interchange: a balanced analysis of low molecular weight heparins J Thromb Thrombolysis 11 3 2001 247 259
2. American Society of Hospital Pharmacists ASHP statement on the formulary system Am J Hosp Pharm 43 1988 2839 2841
3. G.M. McCart, and S. Kayser Therapeutic equivalency of low molecular weight heparins Ann Pharmcother 36 2002 1042 1057
4. P. Prandoni Low molecular weight heparins: are they interchangeable? Yes J Thromb Hemostasis 1 2003 10 11
5. G. Nenci Low molecular weight heparins: are they interchangeable? No J Thromb Hemostasis 1 2003 12 13
6. R.L. Bick, and J. Fareed Low Molecular weight heparin: differences and similarities in approved preparations in the United States Clin Appl Throm Hemost 5 Suppl 1 1999 S63 S66
7. J. Fareed, D. Hoppensteadt, and W. Jeske Low molecular weight heparins. Are they different? Can J Cardiol 14 Suppl E 1998 28E 34E
8. J. Fareed, S. Haas, and A. Sasahara Past, present and future considerations on low molecular weight heparins differentiation: an epilogue Sem Thromb Hemost 25 Suppl 3 1999 145 147
9. R.J. Linhardt, and N.S. Gunay Production and chemical processing of low molecular weight heparins Semin Thromb Hemostas 25 Suppl 3 1999 5 16
10. S.L. Nightingale From the Food and Drug Administration JAMA 270 14 1993 1672
11. J. Hirsch, T.E. Warkentin, and S.G. Shaughnessy Heparin and low molecular weight heparin: mechanisms of action, pharamcokinetics, dosing considerations, monitoring, efficacy, and safety Chest 114 Suppl 5 1998 489S 510S
12. T.J. Ryan, and E.M. Antman 1999 update. ACC/AHA guidelines for the management of patients with acute myocardial infarction J Am Col Cardiol 34 3 1999 890 911
13. J. Fareed, K. Fu, and D. Hoppensteadt Pharmacokinetics of low molecular weight heparins in animal models Semin Thromb Hemost 25 Suppl 3 1999 51 55
14. B. Kaiser, C.M. Kirchmaier, and H.K. Breddin Preclinical biochemistry and pharmacology of low molecular weight heparins in vivo Semin Thromb Hemost 25 Suppl 3 1999 35 42
15. M. Cohen, C. Demers, and E.P. Gurfinkel A comparison of low molecular weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and safety of subcutaneous enoxaparin in non-Q wave coronary events study group (ESSENCE) N Engl J Med 337 7 1997 447 452
16. W. Klein, A. Buchwald, and M.D. Arnd Fragmin in unstable angina pectoris or in non-Q wave acute myocardial infarction. Fragmin in unstable coronary artery disease (FRIC) Am J Cardiol 80 5A 1997 30E 34E
17. FRISC study group Low molecular weight heparin during instability in coronary artery disease. Fragmin during instability in coronary artery disease (FRISC) Lancet 347 9001 1998 561 568
18. S. Mousa, and J. Fareed Overview: from heparin to low molecular weight heparins: beyond anticoagulation Curr Opin Invest Drug 2 8 2001 1077 1080
19. J. Fareed, A. Kumar, and J.M. Walenga Antithrombotic actions and pharmacokinetics of heparin fractions and fragments Nouv Rev Fr Hematol 26 1984 267 275
20. J. Fareed, J.M. Walenga, and A. Racanelli Validity of the newly established low-molecular-weight heparin standard in cross-referencing low-molecular-weight heparins Haemostasis 18 Suppl 3 1988 33 47
21. J.S. Barrett, J.W. Hainer, and D.M. Kornhauser Anticoagulant pharmacodynamics of tinzaparin following 175 IU/kg subcutaneous administration to healthy volunteers Thromb Res 101 2001 243 254
22. J. Fareed S. Haas A. Sasahara Differentiation of low molecular weight heparins. Applied and clinical considerations [special issue] Semin Thromb Hemost 25 3 1999
23. J. Fareed, J.M. Walenga, and D. Hoppensteadt Comparative study on the in vitro and in vivo activities of seven low-molecular-weight heparins Haemostasis 18 Suppl 3 1988 3 15
24. J. Fareed, J.M. Walenga, and K. Williamson Studies on the antithrombotic effects and pharmacokinetics of heparin fractions and fragments Semin Thromb Hemost 11 1 1985 56 74
25. Memorandum on a provisional international standard for heparin Bull Health Organ League Nations 1942 151 154
26. T.W. Barrowcliffe, A.D. Curtiss, and E.A. Johnson An international standard for low molecular weight heparin Thromb Haemost 60 1988 1 7
27. B. Mulloy, C. Gee, and S.F. Wheeler Molecular weight measurements of low molecular weight heparins by gel permeation chromatography Thromb Haemost 77 4 1997 668 674
28. J.P. Cambus, S. Saivin, and J.J. Heilmann The pharmacodynamics of tinzaparin in healthy volunteers Br J Hematol 116 2002 649 652
29. Abboud L. Bush acts to speed generics to market. Wall Street Journal. June12, 2003;A3, vol. CCXLI 114